A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Completed · Phase 3

Conditions studied: Waldenström's Macroglobulinemia

In brief

This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

Key facts

Study ID
NCT03053440
Run by
BeiGene
People needed
201
Starts
2017-01-25
Expected to finish
2022-06-21
Last updated by the study team
2024-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.